Back
ESC2025 Premium Access

DLCO, a potential indicator of pulmonary microvasculopathy, and its association with exercise capacity, oxygenation, and hemodynamics in patients with chronic thromboembolic pulmonary hypertension aft

Session: Chronic thromboembolic pulmonary hypertension: management strategies
Topic: Pathophysiology and Mechanisms
Speaker: Doctor Y. Yanagisawa (Tokyo, JP)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Yoshiaki Yanagisawa

Kyorin University Faculty of Medicine, Tokyo (Japan)
0 follower

5 more presentations in this session

Medical therapy for non-operable chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty: CTEPH AC registry across Japan

Speaker: Doctor Y. Taniguchi (Kobe, JP)

Access
Abstract
Slides
Video
Like
Thumbnail

Impact of medical therapy on balloon pulmonary angioplasty outcomes in chronic thromboembolic pulmonary hypertension

Speaker: Doctor L. Alajbegovic (Vienna, AT)

Access
Abstract
Slides
Video
Like
Thumbnail

Experience of nine years of balloon pulmonary angioplasty in a single centre: short term results

Speaker: Doctor M. Salvi (Bologna, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Post-pulmonary endarterectomy hemodynamic changes evaluated by pulmonary artery pressure-volume loops

Speaker: Miss C. Palacios Echavarren (Logrono, ES)

Access
Abstract
Slides
Video
Like
Thumbnail

Transcollateral retrograde balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: Insights from a Japanese expert center

Speaker: Doctor N. Ikeda (Tokyo, JP)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Chronic thromboembolic pulmonary hypertension: management strategies

Speakers: Doctor Y. Yanagisawa, Doctor Y. Taniguchi, Doctor L. Alajbegovic, Doctor M. Salvi, Miss C. Palacios Echavarren...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources